SCHEMBL6574169

SCHEMBL6574169

CCOC(=O)C(OC(=O)OC1C[N+]2(C)CCC1CC2)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 9/20 0.50
CHRM1 P11229 7/20 0.50
CHRM3 P20309 7/20 0.50
CHRM4 P08173 3/20 0.50
CHRM5 P08912 3/20 0.50
SLC6A4 P31645 3/20 0.50
CYP2D6 P10635 2/20 0.50
KCNH2 Q12809 1/20 0.50
RGS12 O14924 1/20 0.49
APOBEC3A P31941 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
LMNA P02545 2/20 0.39
THRB P10828 2/20 0.39
BLM P54132 2/20 0.39
PMP22 Q01453 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6574291 0.79 CHRM3 (0.54) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL6577643 0.76 CHRM2 (0.60) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL231642 0.74 CHRM3 (0.47) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL231643 0.74 CHRM3 (0.47) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL12014464 0.72 CHRM2 (0.53) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL3783863 0.72 CHRM2 (0.53) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL13240866 0.72 CHRM2 (0.53) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL6575282 0.72 LMNA (0.59) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL10256911 0.71 CHRM2 (0.64) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL6574111 0.70 CHRM3 (0.41) CHRM2CHRM1CHRM3CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383730-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE Aryx Therapeutics (US) 2004-01-28 EP claimed
WO-2002096855-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE ARYX THERAPEUTICS (US) 2002-12-05 WO claimed
US-20020169208-A1 Novel anticholinergic compounds and methods of use ARYX THERAPEUTICS 2002-11-14 US claimed
EP-1383730-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE Aryx Therapeutics (US) 2004-01-28 EP disclosed
WO-2002096855-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE ARYX THERAPEUTICS (US) 2002-12-05 WO disclosed
US-20020169208-A1 Novel anticholinergic compounds and methods of use ARYX THERAPEUTICS 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169208-A1 Novel anticholinergic compounds and methods of use CHRM3, CHRM5, CHRM2 CHRM2 3/4885CHRM1 9/4885CHRM3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.